NHS England has refused funding for a breakthrough drug that can help children with a life threatening disease live long and healthy lives. The drug, everolimus, treats tuberous sclerosis complex, or TSC, which can cause non-cancerous tumors to grow and cause seizures and infections. Life expectancy can be as little as 12 months, but everolimus has been demonstrated to shrink these tumors and stabilize patients. The drug is expensive, but treating the damage caused by TSC is even more expensive. NHS England will reevaluate funding for everolimus in 2017.
- October 10, 2016
- by :